Origin Therapeutics Holdings (XCNQ:ORIG) EV-to-EBITDA : 4.91 (As of Jun. 10, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Origin Therapeutics Holdings EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Origin Therapeutics Holdings's enterprise value is C$-3.65 Mil. Origin Therapeutics Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was C$-0.74 Mil. Therefore, Origin Therapeutics Holdings's EV-to-EBITDA for today is 4.91.

The historical rank and industry rank for Origin Therapeutics Holdings's EV-to-EBITDA or its related term are showing as below:

XCNQ:ORIG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 10.66
Current: 4.91

During the past 2 years, the highest EV-to-EBITDA of Origin Therapeutics Holdings was 10.66. The lowest was 0.00. And the median was 0.00.

XCNQ:ORIG's EV-to-EBITDA is not ranked
in the Drug Manufacturers industry.
Industry Median: 14.17 vs XCNQ:ORIG: 4.91

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-10), Origin Therapeutics Holdings's stock price is C$0.025. Origin Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was C$-0.053. Therefore, Origin Therapeutics Holdings's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Origin Therapeutics Holdings EV-to-EBITDA Historical Data

The historical data trend for Origin Therapeutics Holdings's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Origin Therapeutics Holdings EV-to-EBITDA Chart

Origin Therapeutics Holdings Annual Data

Trend

Sep21

Sep22

EV-to-EBITDA

2.64

Origin Therapeutics Holdings Quarterly Data
	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EV-to-EBITDA	Get a 7-Day Free Trial				2.23	2.64	4.35	2.19	2.22

Competitive Comparison of Origin Therapeutics Holdings's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Origin Therapeutics Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Origin Therapeutics Holdings's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Origin Therapeutics Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Origin Therapeutics Holdings's EV-to-EBITDA falls into.

Origin Therapeutics Holdings EV-to-EBITDA Calculation

Origin Therapeutics Holdings's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	-3.649	/	-0.743
	=	4.91

Origin Therapeutics Holdings's current Enterprise Value is C$-3.65 Mil.
Origin Therapeutics Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.74 Mil.

Origin Therapeutics Holdings (XCNQ:ORIG) EV-to-EBITDA Explanation

Origin Therapeutics Holdings's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.025	/	-0.053
	=	At Loss

Origin Therapeutics Holdings's share price for today is C$0.025.
Origin Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.053.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Origin Therapeutics Holdings EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Origin Therapeutics Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.